At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 10-30 16:00:00 EDT
16.65
-0.56
-3.25%
盘后16.68
+0.03+0.18%
19:30 EDT
High17.04Low16.48Vol960.84K
Open16.76D1 Closing17.21Amplitude3.25%
Mkt Cap2.22BTradable Cap2.15BTotal Shares133.05M
T/O16.03MT/O Rate0.74%Tradable Shares129.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aurinia Pharmaceuticals Inc. Expected to Post Earnings of 22 Cents a Share - Earnings Preview
Reuters  ·  10-30 22:04
Aurinia Pharmaceuticals Inc. Expected to Post Earnings of 22 Cents a Share - Earnings Preview
Aurinia Pharmaceuticals Q3 Operating Income USD 35.363 Million
Reuters  ·  10-30 20:14
Aurinia Pharmaceuticals Q3 Operating Income USD 35.363 Million
Canada's Aurinia Q3 Revenue Rises 14% on Lupkynis Sales
Reuters  ·  10-30 20:12
Canada's Aurinia Q3 Revenue Rises 14% on Lupkynis Sales
Aurinia Pharmaceuticals Shares Fall 3.4% Premarket After Quarterly Results
THOMSON REUTERS  ·  10-30 20:07
Aurinia Pharmaceuticals Shares Fall 3.4% Premarket After Quarterly Results
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
Benzinga Earnings  ·  10-30 20:06
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.22
MT Newswires Live  ·  10-30 20:04
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q3 EPS $0.23, vs. FactSet Est of $0.22
Aurinia Pharmaceuticals Nine-Month Net Income Rises 35% to $103.47 Million
Reuters  ·  10-30 20:04
Aurinia Pharmaceuticals Nine-Month Net Income Rises 35% to $103.47 Million
Aurinia Pharmaceuticals Q3 EPS USD 0.23
THOMSON REUTERS  ·  10-30 20:00
Aurinia Pharmaceuticals Q3 EPS USD 0.23
Aurinia Pharmaceuticals Outlook FY Net Product Sales $310 Million - $315 Million
THOMSON REUTERS  ·  10-30 20:00
Aurinia Pharmaceuticals Outlook FY Net Product Sales $310 Million - $315 Million
Aurinia Pharmaceuticals Outlook FY Revenue USD 325-330 Million
THOMSON REUTERS  ·  10-30 20:00
Aurinia Pharmaceuticals Outlook FY Revenue USD 325-330 Million
Aurinia Pharmaceuticals Q3 Product Revenue USD 79.418 Million
THOMSON REUTERS  ·  10-30 20:00
Aurinia Pharmaceuticals Q3 Product Revenue USD 79.418 Million
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
THOMSON REUTERS  ·  10-30 20:00
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals price target raised to $18 from $17 at TD Cowen
TIPRANKS  ·  10-21
Aurinia Pharmaceuticals price target raised to $18 from $17 at TD Cowen
13D Filings
Dow Jones  ·  09-05
13D Filings
LB Pharmaceuticals Names Joseph Miller CFO
MT Newswires Live  ·  09-03
LB Pharmaceuticals Names Joseph Miller CFO
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch
Simply Wall St.  ·  08-26
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Simply Wall St.  ·  08-22
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Aurinia Shares Gains After Settling Patent Lawsuit with Teva
Dow Jones  ·  08-20
Aurinia Shares Gains After Settling Patent Lawsuit with Teva
Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
TIPRANKS  ·  08-20
Aurinia Pharmaceuticals (AUPH) Gets a Buy from TD Cowen
Aurinia settles patent litigation with Teva
TIPRANKS  ·  08-20
Aurinia settles patent litigation with Teva

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--